Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARINA C GARASSINO

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1053999599
CMS profile
9736255
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$92,270.62

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARINA C GARASSINO

NPI 1053999599 · CMS profile ID 9736255

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053999599?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARINA C GARASSINO, NPI 1053999599, CMS profile ID 9736255. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053999599?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MARINA C GARASSINO, NPI 1053999599, CMS profile ID 9736255. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053999599?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MARINA C GARASSINO, NPI 1053999599, CMS profile ID 9736255, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1053999599?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $92,270.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–67 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $14.0203/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234577325 CMS
Merck Sharp & Dohme LLC $27.2403/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238001632 CMS
Merck Sharp & Dohme LLC $47.1403/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238002646 CMS
Merck Sharp & Dohme LLC $36.6703/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238033702 CMS
AstraZeneca Pharmaceuticals LP $3,280.0003/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206307277 CMS
Regeneron Pharmaceuticals, Inc. $416.9703/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213237993 CMS
Regeneron Pharmaceuticals, Inc. $73.1703/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213237995 CMS
Regeneron Pharmaceuticals, Inc. $94.4503/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213237997 CMS
Regeneron Pharmaceuticals, Inc. $33.0303/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213237999 CMS
Regeneron Pharmaceuticals, Inc. $83.6903/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213238001 CMS
Regeneron Pharmaceuticals, Inc. $172.9003/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213237991 CMS
Regeneron Pharmaceuticals, Inc. $175.9002/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213237989 CMS
AstraZeneca Pharmaceuticals LP $134.5802/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206806493 CMS
Bayer Healthcare Pharmaceuticals Inc. $700.0002/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1225545389 CMS
Genentech USA, Inc. $109.6802/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211542253 CMS
Regeneron Pharmaceuticals, Inc. $35.2501/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213237985 CMS
Regeneron Pharmaceuticals, Inc. $705.9901/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213237987 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $61,372.53 31
PY2022 $84,324.09 49
PY2023 $72,652.17 68
PY2024 $86,815.26 72
PY2025 $92,270.62 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,008.10 9
PY2025 Principal investigator $125,123.19 11
PY2024 Recipient $2,486.84 4
PY2024 Principal investigator $168,290.43 8
PY2023 Principal investigator $278,638.38 15
PY2022 Recipient $2,030.57 4
PY2022 Principal investigator $37,167.00 2
PY2021 Recipient $2,159.65 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Regeneron Pharmaceuticals, Inc. $21.08 11/08/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184117631
Recipient Regeneron Pharmaceuticals, Inc. $95.37 11/08/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184117633
Principal investigator 1 Eli Lilly and Company $499.84 10/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187893554
Principal investigator 1 ABBVIE INC. $13,728.00 09/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202509862
Principal investigator 1 Merck Sharp & Dohme LLC $33,210.24 08/31/2025 Non-covered Recipient Entity
University of Chicago Medical Center
A Phase 3 Study of Pembrolizumab in combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel followed by Pembrolizumab with or without maintenance MK 2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer No dispute reported 06/30/2026 1232924374
Principal investigator 1 ABBVIE INC. $15,210.00 08/06/2025 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202503421
Principal investigator 1 Daiichi Sankyo Inc. $5,720.00 08/04/2025 Non-covered Recipient Entity
University Of Chicago
DS1062-A-U301 No dispute reported 06/30/2026 1223386351
Principal investigator 1 AstraZeneca UK Limited $5,720.00 07/30/2025 Non-covered Recipient Entity
UNIV OF CHICAGO
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) No dispute reported 06/30/2026 1185537173
Principal investigator 1 Mirati Therapeutics, Inc. $9,555.00 07/03/2025 Non-covered Recipient Entity
The University Of Chicago Kovler Diabetes Center
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio No dispute reported 06/30/2026 1236530511
Principal investigator 1 ABBVIE INC. $3,900.00 07/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202494339
Recipient Regeneron Pharmaceuticals, Inc. $141.14 04/14/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184117629
Recipient Regeneron Pharmaceuticals, Inc. $139.68 04/09/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184117627
Recipient Regeneron Pharmaceuticals, Inc. $84.84 04/03/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184117625
Recipient Regeneron Pharmaceuticals, Inc. $141.69 03/28/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184117623
Recipient Regeneron Pharmaceuticals, Inc. $24.24 03/18/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184117621
Recipient Regeneron Pharmaceuticals, Inc. $327.49 03/07/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184117619
Recipient Regeneron Pharmaceuticals, Inc. $32.57 01/30/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184117617
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,533.06 01/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO MEDICINE
A Phase I II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti-TIGIT Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non-small Cell Lung Cancer No dispute reported 06/30/2026 1185537175
Principal investigator 1 Mirati Therapeutics, Inc. $28,036.45 01/15/2025 Non-covered Recipient Entity
The University Of Chicago Kovler Diabetes Center
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236530515
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10.60 01/09/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab with or without Carboplatinin Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04) No dispute reported 06/30/2026 1185537171